34 results about "Seasonal allergy" patented technology

Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.

A method for treatment or prophylaxis of a disease state or other physiological condition, e.g., autism, delayed development, acid reflux disease, vaginal yeast infections, impaired hearing, chronic ear infections, seasonal allergies, Fibromyalgia syndrome, Crohn's disease, colitis, irritable bowel syndrome, interstitial cystitis, acne, sinusitis, rheumatoid arthritis, chronic fatigue syndrome, asthma, attention deficit disorder, attention deficit / hyperactivity disorder, rosacea, multiple sclerosis, hyperglycemia, or Ménière's disease, by administration of an anti-fungal composition that includes at least one of the bacilli (1) Bacillus subtilis, (2) Lactobacillus sporogenes, and (3) Streptococcus faecalis.

For use in residential buildings, a device to draw in outside air and have it mix with the air inside the building to improve indoor air-quality through dilution and building pressurization. Pressurizing a building even slightly inhibits air infiltration of pollutants such as pollen, mold spores, and seasonal allergens from entering penetrations ie, poor door and window seals, chimney, bathroom, dryer and stove exhaust ducts from entering the building.

Therapeutic composition and method for treating or preventing various conditions and diseases, including inflammatory conditions, allergies, particularly seasonal allergies, and the common cold. In a preferred embodiment, the therapeutic composition is a formulation comprising an antibiotic, preferably a tetracycline, most preferably doxycycline, which has not been chemically modified to eliminate antimicrobial efficacy. The antibiotic is preferably in a vehicle to form a salve or paste for topical application to the skin or the nasal cavity. The therapeutic composition most preferably is a self-applied formulation that consists essentially of a tetracycline, most preferably doxycycline, which has not been chemically modified to eliminate antimicrobial efficacy, and a vehicle such as boric acid, zinc oxide or petroleum jelly.

The invention provides a biological anti-allergy compound. The compound comprises the following raw materials: water, glycerin, a collagen crosslinked body, a Paeonia lactiflora extract product, a Tilia europaea extract product, an Arnica montana extract product, an Althaea officinalis root extract product, oligopeptide-1, and oligopeptide-6. The product contains effective components of Paeonia lactiflora, Tilia europaea, and the like, and has efficacies for diminishing inflammation, resisting inflammation, relieving itching, relieving pain, and preventing allergy; the product aims at drug allergy, diet allergy, seasonal allergy, eczema allergy, eczema in infant, and infantile eczema, and even aims at skin allergy due to improper usage of cosmetics with good control and repair effects; the product can effectively alleviate allergy, and long-term usage of the product has effects for preventing and improving sequelae of allergy.

The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 seconds, preferably in less than 40 seconds, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilising agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis.

The invention relates to the technical field of traditional Chinese medicines, and especially relates to a traditional Chinese medicinal composition for treating seasonal allergic rhinitis. The traditional Chinese medicinal composition for treating seasonal allergic rhinitis is prepared by using the following medicinal materials, by weight, 10-15 parts of Blackberrylily Rhizome, 10-15 parts of apricot kernel, 4-8 parts of Radix Platycodonis, 10-15 parts of Aster tataricus, 10-15 parts of Common Coltsfoot Flower, 10-15 parts of (fried) lumbricus, 8-13 parts of gingko, 4-8 parts of Divaricate Saposhnikovia Root, 6-11 parts of cassia twig, 10-15 parts of white peony root, 6-11 parts of Chinese angelica, 6-11 parts of licorice root, 8-13 parts of Negundo Chastetree Fruit, 12-18 parts of perilla fruit, 6-11 parts of lily, 10-15 parts of Polygonatum sibiricum, 10-15 parts of Herba Centipedae, 12-18 parts of Manchurian wildginger, 6-11 parts of Rhizoma Anemarrhenae, 10-15 parts of datura flower and 12-18 parts of Chinese ilex. The composition is mainly used for treating the seasonal allergic rhinitis, especially progressive seasonal allergic rhinitis difficult to cure clinically; and years of clinic application researches show that the total effective rate of the composition on asthmatic suffocating caused by the seasonal allergic rhinitis, seasonal aggravated rhinitis and allergic trachitis can reach 100%.

A method of treating and / or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, pernninal allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2x2.5 mg or 5 mg / day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng / mL to about 4.54 ng / mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng / mL to about 5.0 ng / mL is disclosed.

The disclosure provides ophthalmic compositions, systems and methods for the treatment of ocular surface allergies. More particularly the present invention relates to compositions of bromfenac for the treatment of the signs and symptoms of ocular surface allergies due to seasonal allergies.

A pharmaceutical composition useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitus, allergy, asthma, allergic asthma and / or inflammation, in a mammalian organism in need of such treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from a) montelukast, b) 1-(((R)- (3-(2-(6,7- difluoro-2- quinolinyl)ethenyl) phenyl)-3-(2- (2-hydroxy-2- propyl)phenyl) thio)methylcyclopropaneacetic acid; c) 1-(((1(R)-3 (3-(2-(2,3- dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl) -3-(2-(1-hydroxy-1- methylethyl) phenyl)propyl) thio)methyl) cyclopropaneacetic acid; d) pranlukast; or f) [2-[[2-(4-tert -butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixture with ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.

The invention relates to an anti-cold medical composition consisting of active components of loratadine, acetaminophen, pseudoephedrine sulfate and pharmaceutically acceptable auxiliary materials. The medical composition is a double-layered sustained-release tablet with a quick release outer layer coating a sustained-release core. The quick release outer layer comprises loratadine and pseudoephedrine sulfate while the sustained-release part comprises acetaminophen and pseudoephedrine sulfate. The double-layered composition is used for relieving sneeze, rhinorrhea, nasal obstruction, laryngeal discomfort, weakness, fever, sore muscle, headache and the like which are caused by cold or seasonal allergic rhinitis.

The present invention discloses a medicine fexofenadine hydrochloride dripping pills preparation for effectively curing seasonal allergic rhinitis and chronic idiopathic urticaria and its preparation process. It is made up by using fexofenadine hydrochloride and matrix for making dripping pills.

The invention relates to an application of silicone oil in preparing an allergen retarder. Silicone oil can be smeared on the inner wall of the nasal cavity to stick allergens in the air to inhibit the allergic reaction, thereby performing the functions of preventing and relieving the allergic rhinitis. The inventor discovers that when the silicone oil is used before the stage of attack of the seasonal allergic rhinitis, the attack of the seasonal allergic rhinitis can be effectively prevented; after the attack of the seasonal allergic rhinitis, a patient continuously uses the silicone oil for two weeks, and then, the attack degree of the seasonal allergic rhinitis can be effectively relieved; and for perennial allergic rhinitis, the patient continuously uses the silicone oil for two weeks, and then, the attack degree of the perennial allergic rhinitis can also be effectively relieved.

The invention relates to an internal medicine combined with Chinese and western medicine for curing allergic rhinitis and a preparation method thereof; 6 to 15 parts of inverted grass, 9 to 15 parts of dandelion, 6 to 12 parts of angelica, 6 to 9 parts of rhizoma ligustici wallichii, 6 to 9 parts of radix sophorae falvescentis, 3 to 6 parts of mint, 9 to 12 parts of fructus xanthil, 6 to 12 parts of burdock-seed, 1 to 9 parts of licorice roots northwest origin, 0.3 to 0.6 part of paracetamol, 0.004 to 0.012 part of chlorpheniramine, 0.3 to 0.6 part of calcium lactate, and 0.3 to 0.9 part of caffeinum natrio benzoicum are prepared in parts by weight for standby use; and the medicine materials are respectively decocted, concentrated, air-dried, crushed, mixed with western medicine to be screened and processed, and tablets or capsules are prepared. The medicine can treat seasonal allergic rhinitis, can remove symptoms and recover the health after being taken for 1 to 2 days, and can cure the diseases after being continuously taken for 6 to 12 days; and can treat patients with seasonal allergy rhinitis, can fully remove the symptoms after being taken for 6 to 12 days, and cure the diseases after the health state is kept for 4 to 8 weeks. The finished medicine can be produced industrially, the dose for a patient is 3 times per day, and 1 to 2g per time. The preparation combined with Chinese and western medicine of the invention not only can diminish inflammation, dissipate blood stasis, invigorate blood circulation, eliminate swelling and enlighten, but also has the effect of desensitization and better clinical effect, and has won the trust of the majority of patients.

An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea.

The invention discloses a method for treating seasonal allergic rhinitis. The effective parts of plants that cause allergy such as roots, stems, leaves, flowers, fruits, and the like, are collected; in particular, compositae artemisia plants. Moreover, other natural plants such as herbs, bushes, arbors, are added to treat allergic rhinitis; the treatment does not need any drug or surgery; and a product contains allergen and can well treat allergic rhinitis. The invention also discloses a formula of the product mentioned above.

The present invention relates to a low-dose composition of budesonide, which is suitable to use the budesonide on the mucous memebane to treat the nasal symptoms which are relevant to the seasonal allergic rhinitis, the perennial allergic rhinitis, perennial non-allergic rhinitis and the rhinopolypus, and prevent the postoperative polypi, chronic sinusitis and recurrent sinusitis, the composition includes the budesonide whose effective dose is below 16 mcg and the liquid carrier that is acceptable at the pharmacy.

The present invention relates to a nasal composition comprising an anti-allergic oil derived from plant; and an oil-based barrier-forming preparation. The composition may be used in preventing and / or treating allergic disorders of the nasal cavity, including seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis.

The invention discloses a mizolastine sustained release pellet, which consists of a drug-containing pellet body and a coating layer, wherein the drug-containing pellet body is covered by the coating layer; the drug-containing pellet body consists of 10mg of mizolastine, 70mg of a blank pellet core, 120-220mg of a filling agent, 25-125mg of a lubricating agent and 5-35mg of a binding agent; the coating layer consists of 35-175mg of Eudragit NE30D and 5-52mg of talcum powder; and a preparation method comprises the following steps: 1, preparing materials; 2, mixing; 3, preparing the binding agent; 4, preparing the pellet; 5, preparing a coating agent; 6, coating; 7, filling; and 8, aluminum-molding and obtaining a finished product. The mizolastine sustained release pellet disclosed by the invention is mainly used for treating skin allergy symptoms such as urticaria and the like, seasonal allergic rhinitis (pollinosis) and perennial allergic rhinitis; the sustained release pellet, which makes use of two advanced technologies, namely a novel sustained release preparation and a novel pellet preparation, is stable in therapeutic effect and relatively high in bioavailability, and the sustained release pellet has the advantages of being good in drug stability, convenient in packaging, transportation and storage and the like; and the preparation is simple and easy to implement and is applicable to industrial production.

The invention provides a flu treatment formula and a preparation method thereof. The flue treatment formula comprises the following components by mass: 6-15g of folium mori, 5-20g of almonds, 3-9g ofadenophora stricta, 7-14g of fritillaria thun-bergli, 9-25g of fermented blank beans and 6-18g of dried tangerine or orange peel. Due to addition of traditional Chinese medicine pieces such as foliummori, almonds, denophora stricta, fritillaria thun-bergli, fermented blank beans and dried tangerine or orange peel, a granule medicine can be prepared, the flu treatment formula is capable of expelling wind and removing dampness and is capable of treating flu cough in autumn, particularly symptoms of thirst and asthenic fever caused by dry cough and improving treatment effects on flu and seasonalallergy, and drug resistance of western medicines can be avoided.

The present invention discloses a medicine terfenadine dripping pills preparation for effectively curing the diseases of seasonal and non-seasonal allergic rhinitis, urticaria and hay fever and its preparation process. It is made up by using terfenadine and matrix for making dripping pills.

The invention discloses traditional Chinese medicine composition for repairing skin, a mask formula, a preparation method and an application. The composition is prepared from raw materials in parts bymass as follows: 5-10 parts of mint, 6-11 parts of herba violae, 2-6 parts of radix angelicae, 6-8 parts of radix ginseng, 10-13 parts of fructus forsythiae, 4-8 parts of hay, 7-12 parts of rhizoma coptidis, 4-13 parts of cortex phellodendri, 6-9 parts of fructus schisandrae chinensis, 2-5 parts of frankincense, 2.5-4 parts of myrrh, 1-7 parts of pearl powder, 1-8 parts of natural indigo, 0.5-2 parts of trehalose, 0.03-0.08 parts of betaine, 0.05-0.1 parts of disodium EDTA, 0.5-1 part of butanediol, 6-12 parts of glycerin, 0.05-0.15 parts of propylene glycol, 0.1-0.3 parts of ethylhexyl plamitate, 0.07-0.12 parts of polydomethylsiloxane, 0.02-0.12 parts of a hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, 0.05-0.19 parts of caprylyl glycol, 0.07-0.13 parts of phenoxyethanol, 0.1-0.6 parts of hexyl glycerin and 280-450 parts of water. The mask has good skin repair functions for facial couperose skin, mite allergic skin, mite acne and seasonal allergic skin problems byimproving subcutaneous cell nutrition.